Deerfield Management IONS Position
Exited8-Fund ConvergenceDeerfield Management exited their position in Ionis Pharmaceuticals Inc. (IONS) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
IONS is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Eplontersen in 14 days (Apr 30, 2026), making the timing of Deerfield's position particularly relevant.
Short interest stands at 11.1% of float with 6.2 days to cover, indicating significant bearish positioning against the stock.
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Full company profile →Short Interest
11.1%
6.2 days to cover
Deerfield Management IONS Position History
Frequently Asked Questions
Does Deerfield Management own IONS?
No. Deerfield Management exited their position in Ionis Pharmaceuticals Inc. (IONS) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own IONS?
8 specialist biotech hedge funds currently hold IONS, including Deep Track Capital, BVF Partners, Baker Bros. Advisors and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy IONS?
Deerfield Management's position in IONS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's IONS position increasing or decreasing?
Deerfield Management completely exited their IONS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IONSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →